Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy-Reference-Cited by-同舟云学术

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Published:2015-10 Issue:2 Volume:67 Page:4-17
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Swaika Abhisek,Hammond William A.,Joseph Richard W.

Publisher

Elsevier BV

Reference131 articles.

1. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction;Abiko;Clin. Cancer Res.,2013

2. Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired;Ahmadzadeh;Blood,2009

3. BCG immunotherapy of bladder cancer: 20 years on;Alexandroff;Lancet,1999

4. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC);Amin;ASCO Meet. Abstr.,2014

5. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells;Andorsky;Clin. Cancer Res.,2011

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin‐Like Growth Factor 1 Receptor Expression for Predicting PD‑1/PD‑L1 Inhibitor Response in Hypopharyngeal Squamous Cell Carcinoma;World Journal of Otorhinolaryngology - Head and Neck Surgery;2025-05-19

2. Expression of nuclear receptors and glucose metabolic pathway proteins in sebaceous carcinoma: Androgen receptor and monocarboxylate transporter 1 have a key role in disease progression;Oncology Letters;2024-10-04

3. Exosomes of immune cell origin and their therapeutic potential for tumors;VIEW;2024-09-02

4. From antigen uptake to immune modulation: the multifaceted potential of peptide nanofibers as vaccine nanocarriers;Materials Advances;2024

5. Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment;Current Topics in Medicinal Chemistry;2023-12